Guidance Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$346K Buy
296
+7
+2% +$7.15K 0.07% 191
2026
Q1
$286K Sell
289
-1,049
-78% -$1.06M 0.06% 206
2025
Q4
$1.46M Sell
1,338
-34
-2% -$32.5K 0.36% 57
2025
Q3
$1.13M Buy
1,372
+76
+6% +$56.6K 0.3% 79
2025
Q2
$988K Buy
1,296
+25
+2% +$19.4K 0.28% 83
2025
Q1
$1.05M Buy
1,271
+84
+7% +$69.9K 0.32% 60
2024
Q4
$933K Buy
+1,187
New +$983K 0.29% 68

Other funds holding LLY

Guidance Capital's LLY Position: Q2 2026 in Review

Guidance Capital increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $7.15K and bringing the position to 296 shares worth $346K. The position accounts for 0.07% of the portfolio, ranked #191.

Guidance Capital first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.46M in Q4 2025. 1,103 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Guidance Capital held 296 shares of Eli Lilly worth $346K as of Q2 2026.
  • Guidance Capital bought 7 Eli Lilly shares in Q2 2026, an estimated $7.15K.
  • Eli Lilly made up 0.07% of Guidance Capital's portfolio in Q2 2026, its #191 holding.
  • Guidance Capital first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • Guidance Capital's Eli Lilly position peaked at $1.46M in Q4 2025.
  • 1,103 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Guidance Capital's 13F filing for Q2 2026, filed 20 Jul 2026.